3.05
0.54 (21.51%)
| Penutupan Terdahulu | 2.51 |
| Buka | 2.48 |
| Jumlah Dagangan | 1,530,151 |
| Purata Dagangan (3B) | 1,252,766 |
| Modal Pasaran | 117,309,352 |
| Harga / Jualan (P/S) | 255.50 |
| Harga / Buku (P/B) | 16.73 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Aug 2025 - 11 Aug 2025 |
| EPS Cair (TTM) | -0.830 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 10.50% |
| Nisbah Semasa (MRQ) | 2.22 |
| Aliran Tunai Operasi (OCF TTM) | -19.11 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -10.84 M |
| Pulangan Atas Aset (ROA TTM) | -97.10% |
| Pulangan Atas Ekuiti (ROE TTM) | -290.21% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Gain Therapeutics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.75 |
|
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 3.78% |
| % Dimiliki oleh Institusi | 8.14% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Potomac Capital Management, Inc. | 31 Dec 2025 | 1,010,000 |
| Jones Financial Companies Lllp | 31 Dec 2025 | 702,213 |
| Cambridge Investment Research Advisors, Inc. | 31 Dec 2025 | 568,645 |
| Dme Capital Management, Lp | 31 Dec 2025 | 566,130 |
| Cresset Asset Management, Llc | 31 Dec 2025 | 160,000 |
| Lpl Financial Llc | 31 Dec 2025 | 106,550 |
| Julat 52 Minggu | ||
| Median | 8.00 (162.30%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 19 Dec 2025 | 8.00 (162.30%) | Beli | 2.88 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 07 Jan 2026 | Pengumuman | Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week |
| 06 Jan 2026 | Pengumuman | Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287 |
| 18 Dec 2025 | Pengumuman | Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease |
| 18 Dec 2025 | Pengumuman | Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |